Literature DB >> 30527374

COPD and Cardiovascular Disease.

S André1, B Conde2, E Fragoso3, J P Boléo-Tomé4, V Areias5, J Cardoso6.   

Abstract

COPD is one of the major public health problems in people aged 40 years or above. It is currently the 4th leading cause of death in the world and projected to be the 3rd leading cause of death by 2020. COPD and cardiac comorbidities are frequently associated. They share common risk factors, pathophysiological processes, signs and symptoms, and act synergistically as negative prognostic factors. Cardiac disease includes a broad spectrum of entities with distinct pathophysiology, treatment and prognosis. From an epidemiological point of view, patients with COPD are particularly vulnerable to cardiac disease. Indeed, mortality due to cardiac disease in patients with moderate COPD is higher than mortality related to respiratory failure. Guidelines reinforce that the control of comorbidities in COPD has a clear benefit over the potential risk associated with the majority of the drugs utilized. On the other hand, the true survival benefits of aggressive treatment of cardiac disease and COPD in patients with both conditions have still not been clarified. Given their relevance in terms of prevalence and prognosis, we will focus in this paper on the management of COPD patients with ischemic coronary disease, heart failure and dysrhythmia.
Copyright © 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cardiovascular Disease; Chronic obstructive pulmonary disease; Comorbidity; Diagnostic Techniques and Procedures

Mesh:

Year:  2018        PMID: 30527374     DOI: 10.1016/j.pulmoe.2018.09.006

Source DB:  PubMed          Journal:  Pulmonology        ISSN: 2531-0429


  15 in total

1.  Efficacy of tiotropium bromide combined with different doses of fluticasone plus salmeterol DPI in the treatment of stable COPD.

Authors:  Xiao Ma; Jingjing Xu; Jun Yang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Effects of Doxofylline Combined with Ceftazidime on Clinical Efficacy, Drug Safety, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease Complicated with Infection.

Authors:  Ying Wang
Journal:  Med Sci Monit       Date:  2021-08-18

3.  Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study.

Authors:  Rutao Wang; Mariusz Tomaniak; Kuniaki Takahashi; Chao Gao; Hideyuki Kawashima; Hironori Hara; Masafumi Ono; David van Klaveren; Robert-Jan van Geuns; Marie-Claude Morice; Piroze M Davierwala; Michael J Mack; Adam Witkowski; Nick Curzen; Sergio Berti; Francesco Burzotta; Stefan James; Arie Pieter Kappetein; Stuart J Head; Daniel J F M Thuijs; Friedrich W Mohr; David R Holmes; Ling Tao; Yoshinobu Onuma; Patrick W Serruys
Journal:  Clin Res Cardiol       Date:  2021-03-12       Impact factor: 5.460

4.  Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.

Authors:  A Koneti Rao; Fabiola Del Carpio-Cano; Sumalaxmi Janapati; Huaqing Zhao; Helen Voelker; Xiaoning Lu; Gerard Criner
Journal:  J Thromb Haemost       Date:  2021-04-12       Impact factor: 16.036

5.  Assessment of fully automatic segmentation of pulmonary artery and aorta on noncontrast CT with optimal surface graph cuts.

Authors:  Zahra Sedghi Gamechi; Andres M Arias-Lorza; Zaigham Saghir; Daniel Bos; Marleen de Bruijne
Journal:  Med Phys       Date:  2021-10-29       Impact factor: 4.506

6.  Postoperative Delirium in Patients with Chronic Obstructive Pulmonary Disease after Coronary Artery Bypass Grafting.

Authors:  Aleksandra Szylińska; Iwona Rotter; Mariusz Listewnik; Kacper Lechowicz; Mirosław Brykczyński; Sylwia Dzidek; Maciej Żukowski; Katarzyna Kotfis
Journal:  Medicina (Kaunas)       Date:  2020-07-09       Impact factor: 2.430

7.  Association Between Statin Use and Exacerbation of Chronic Obstructive Pulmonary Disease Among Patients Receiving Corticosteroids.

Authors:  Wu-Chien Chien; Kwua-Yun Wang; Yi-Jen Huang; Senyeong Kao; Li-Ting Kao; Chih-Feng Chian; Chi-Hsiang Chung
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-05

8.  Characteristics of COPD Phenotypes in Serbia.

Authors:  Zorica Lazic; Ivana Stankovic; Branislava Milenkovic; Biljana Zvezdin; Sanja Hromis; Slobodan Jankovic; Vojislav Cupurdija
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-16

9.  Acceptance and Potential Impact of the eWALL Platform for Health Monitoring and Promotion in Persons with a Chronic Disease or Age-Related Impairment.

Authors:  Francesco Infarinato; Stephanie Jansen-Kosterink; Paola Romano; Lex van Velsen; Harm Op den Akker; Federica Rizza; Marco Ottaviani; Sofoklis Kyriazakos; Beatrix Wais-Zechmann; Markus Garschall; Stefano Bonassi; Hermie J Hermens
Journal:  Int J Environ Res Public Health       Date:  2020-10-28       Impact factor: 3.390

10.  Co-Morbidity Patterns Identified Using Latent Class Analysis of Medications Predict All-Cause Mortality Independent of Other Known Risk Factors: The COPDGene® Study.

Authors:  Yisha Li; Margaret Ragland; Erin Austin; Kendra Young; Katherine Pratte; John E Hokanson; Terri H Beaty; Elizabeth A Regan; Stephen I Rennard; Christina Wern; Michael R Jacobs; Ruth Tal-Singer; Barry J Make; Gregory L Kinney
Journal:  Clin Epidemiol       Date:  2020-10-27       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.